Patents by Inventor Paul J. Brackemeyer

Paul J. Brackemeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystal Forms
    Publication number: 20190202812
    Abstract: The present invention features crystalline polymorphs of dimethyl (2S,2?S)-1,1,-((2S,2?S)-2,2,-(4,4,-((2S,5S)-1-(4-tert-butylphenyl) pyrrolidine-2,5-diyl) bis (4,1-phenylene)) bis (azanediyl) bis (oxomethylene) bis (pyrrolidine-2,1-diyl)) bis (3-methyl-1-oxobutane-2,1-diyl) dicarbamate i.e. ombitasvir, compound (I), which is a potent HCV NS5A inhibitor. In one embodiment, a crystalline form of Compound (I) has characteristic peaks in the PXRD pattern as shown in one of FIGS. 1-11.
    Type: Application
    Filed: April 25, 2017
    Publication date: July 4, 2019
    Applicant: AbbVie Inc.
    Inventors: Paul J. Brackemeyer, Colleen C. Garrett, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Geoff G. Zhang, Donghua Zhu
  • Crystaline forms of HCV inhibitor
    Patent number: 9469673
    Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (° 2?) of 10.7, 11.6, 12.7, 13.0, 13.2, 13.7, 14.5, 18.7, 19.0, and 19.9 after equilibration at 43% relative humidity.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: October 18, 2016
    Assignee: AbbVie Inc.
    Inventors: Ahmad Y. Sheikh, Moiz Diwan, Agnes E. Pal, Yuchuan Gong, Paul J. Brackemeyer, Geoff Zhang, Seble Wagaw
  • Monohydrate of azaadamantane derivatives
    Patent number: 9464078
    Abstract: The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: October 11, 2016
    Assignee: AbbVie Inc.
    Inventors: Shuang Chen, James J. Napier, Geoff G. Z. Zhang, Paul J. Brackemeyer
  • NOVEL MONOHYDRATE OF AZAADAMANTANE DERIVATIVES
    Publication number: 20150239882
    Abstract: The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.
    Type: Application
    Filed: May 8, 2015
    Publication date: August 27, 2015
    Inventors: Shuang Chen, James J. Napier, Geoff G.Z. Zhang, Paul J. Brackemeyer
  • Cyclopropyl amine derivatives
    Patent number: 9108948
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R3a, R3b, R4, and R5 are defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: August 18, 2015
    Assignee: AbbVie Inc.
    Inventors: Huaqing Liu, Lawrence A. Black, Youssef L. Bennani, Marlon D. Cowart, Zhenping Tian, Paul J. Brackemeyer
  • CRYSTAL FORMS
    Publication number: 20150175612
    Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (°2?) of 6.0, 6.7, 10.4, 11.9, 17.5, 17.7, 21.5, 22.0, 22.7, and 24.2.
    Type: Application
    Filed: December 3, 2014
    Publication date: June 25, 2015
    Applicant: AbbVie Inc.
    Inventors: Paul J. Brackemeyer, Moiz Diwan, Yuchuan Gong, Agnes E. Pal, Ahmad Y. Sheikh, Seble H. Wagaw, Geoff G. Zhang
  • AZAADAMANTANE DERIVATIVES AND METHODS OF USE
    Publication number: 20150158867
    Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.
    Type: Application
    Filed: February 17, 2015
    Publication date: June 11, 2015
    Inventors: Michael R. Schrimpf, Diana L. Nersesian, Kevin B. Sippy, Jianguo Ji, Tao Li, Marc Scanio, Lei Shi, Chih-Hung Lee, William H. Bunnelle, Geoff G.Z. Zhang, Paul J. Brackemeyer, Shuang Chen, Rodger F. Henry
  • Azaadamantane derivatives and methods of use
    Patent number: 8987453
    Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: March 24, 2015
    Assignee: AbbVie Inc.
    Inventors: Michael R. Schrimpf, Diana L. Nersesian, Kevin B. Sippy, Jianguo Ji, Tao Li, Marc Scanio, Lei Shi, Chih-Hung Lee, William H. Bunnelle, Geoff G. Z. Zhang, Paul J. Brackemeyer, Shuang Chen, Rodger F. Henry
  • Crystalline salts of thieno[3,2-c]pyridine kinase inhibitors with improved cpy safety profile
    Patent number: 8633317
    Abstract: Salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: January 21, 2014
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
  • Methods of treating cancer with a thieno[3,2-C]pyridine
    Patent number: 8592589
    Abstract: N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: November 26, 2013
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
  • ABT-263 crystalline forms
    Patent number: 8513243
    Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: August 20, 2013
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
  • ABT-263 crystalline forms
    Patent number: 8362014
    Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: January 29, 2013
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
  • Crystal forms of kinase inhibitors
    Patent number: 8357804
    Abstract: N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: January 22, 2013
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
  • Azaadamantane derivatives and methods of use
    Patent number: 8314119
    Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: November 20, 2012
    Assignee: AbbVie Inc.
    Inventors: Michael R. Schrimpf, Diana L. Nersesian, Kevin B. Sippy, Jianguo Ji, Tao Li, Marc Scanio, Lei Shi, Chih-Hung Lee, William H. Bunnelle, Geoff G. Z. Zhang, Paul J. Brackemeyer, Shuang Chen, Rodger F. Henry
  • NOVEL MONOHYDRATE OF AZAADAMANTANE DERIVATIVES
    Publication number: 20120245195
    Abstract: The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.
    Type: Application
    Filed: September 21, 2011
    Publication date: September 27, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Shuang Chen, James J. Napier, Geoff G.Z. Zhang, Paul J. Brackemeyer
  • [1,2,4]OXADIAZOL-3-YL ACID SALTS AND CRYSTALLINE FORMS AND THEIR PREPARATION
    Publication number: 20120214848
    Abstract: The present invention relates to salts and crystalline forms of [1,2,4]oxadiazol-3-yl]-phenoxy}-cycloalkyl carboxylic acids, processes for their preparation, pharmaceutical compositions comprising such compounds, and methods of using them.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G. Zhang, Paul J. Brackemeyer, Shaung Chen, Thomas D. Gordon
  • Crystalline Forms of Kinase Inhibitors
    Publication number: 20120203002
    Abstract: Salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
    Type: Application
    Filed: June 8, 2011
    Publication date: August 9, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
  • Crystal Forms of Kinase Inhibitors
    Publication number: 20120149726
    Abstract: N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
    Type: Application
    Filed: June 9, 2011
    Publication date: June 14, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
  • ABT-263 CRYSTALLINE FORMS
    Publication number: 20110294811
    Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Application
    Filed: July 28, 2011
    Publication date: December 1, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
  • ABT-263 CRYSTALLINE FORMS
    Publication number: 20110071151
    Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Application
    Filed: September 15, 2010
    Publication date: March 24, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G.Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt